KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Alnylam Pharmaceuticals (ALNY) Other Non-Current Liabilities (2016 - 2025)

Alnylam Pharmaceuticals (ALNY) has disclosed Other Non-Current Liabilities for 14 consecutive years, with $7.6 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Other Non-Current Liabilities fell 98.07% year-over-year to $7.6 million, compared with a TTM value of $7.6 million through Dec 2025, down 98.07%, and an annual FY2025 reading of $7.6 million, down 98.07% over the prior year.
  • Other Non-Current Liabilities was $7.6 million for Q4 2025 at Alnylam Pharmaceuticals, down from $9.8 million in the prior quarter.
  • Across five years, Other Non-Current Liabilities topped out at $422.4 million in Q1 2025 and bottomed at $7.6 million in Q4 2025.
  • Average Other Non-Current Liabilities over 5 years is $216.0 million, with a median of $218.3 million recorded in 2022.
  • The sharpest move saw Other Non-Current Liabilities skyrocketed 557.33% in 2021, then tumbled 98.07% in 2025.
  • Year by year, Other Non-Current Liabilities stood at $99.0 million in 2021, then surged by 114.81% to $212.6 million in 2022, then surged by 45.09% to $308.4 million in 2023, then grew by 27.46% to $393.1 million in 2024, then crashed by 98.07% to $7.6 million in 2025.
  • Business Quant data shows Other Non-Current Liabilities for ALNY at $7.6 million in Q4 2025, $9.8 million in Q3 2025, and $407.5 million in Q2 2025.